Ascendis Pharma A (ASND) Cash & Equivalents (2012 - 2026)

Ascendis Pharma A (ASND) has 15 years of Cash & Equivalents data on file, last reported at $670.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 23.1% year-over-year to $670.6 million; the trailing twelve-month figure through Mar 2026 stood at $670.6 million (up 23.1% YoY), and the FY2025 full-year result was $717.1 million, up 18.41% from the prior year.
• Cash & Equivalents eased to $670.6 million in Q1 2026, from $717.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $848.1 million in Q1 2022 to a low of $278.6 million in Q2 2024.
• A 5-year average of $560.9 million and a median of $559.2 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 40.17% in 2023 and jumped 100.74% in 2025, its largest moves.
• Tracing ASND's Cash & Equivalents over 5 years: stood at $453.8 million in 2022, then decreased by 7.01% to $421.9 million in 2023, then jumped by 41.71% to $597.9 million in 2024, then gained by 19.93% to $717.1 million in 2025, then retreated by 6.48% to $670.6 million in 2026.
• Business Quant data shows ASND's Cash & Equivalents at $670.6 million in Q1 2026, $717.1 million in Q4 2025, and $630.2 million in Q3 2025.